1. Home
  2. ANL vs GCMG Comparison

ANL vs GCMG Comparison

Compare ANL & GCMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

SELL

Current Price

$10.00

Market Cap

998.8M

Sector

N/A

ML Signal

SELL

Logo GCM Grosvenor Inc.

GCMG

GCM Grosvenor Inc.

SELL

Current Price

$13.19

Market Cap

805.6M

Sector

Finance

ML Signal

SELL

Company Overview

Basic Information
Metric
ANL
GCMG
Founded
2004
1971
Country
Singapore
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
998.8M
805.6M
IPO Year
2022
2020

Fundamental Metrics

Financial Performance
Metric
ANL
GCMG
Price
$10.00
$13.19
Analyst Decision
Strong Buy
Buy
Analyst Count
7
5
Target Price
★ $29.50
$15.38
AVG Volume (30 Days)
229.1K
★ 421.9K
Earning Date
08-14-2026
11-09-2026
Dividend Yield
N/A
★ 3.56%
EPS Growth
N/A
★ 1300.00
EPS
N/A
★ 0.34
Revenue
N/A
★ $557,565,000.00
Revenue This Year
$243.83
$6.75
Revenue Next Year
N/A
$11.92
P/E Ratio
★ N/A
$39.71
Revenue Growth
N/A
★ 8.47
52 Week Low
$0.88
$9.30
52 Week High
$17.25
$14.87

Technical Indicators

Market Signals
Indicator
ANL
GCMG
Relative Strength Index (RSI) 41.78 51.54
Support Level $8.95 $12.40
Resistance Level $11.75 $13.59
Average True Range (ATR) 1.03 0.51
MACD 0.20 0.09
Stochastic Oscillator 42.35 48.25

Price Performance

Historical Comparison
ANL
GCMG

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.

About GCMG GCM Grosvenor Inc.

GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG, and absolute return strategies. The company invests maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.

Share on Social Networks: